Skip to main content

Grafa News and Videos — Page 1465

Latest

Grafa

Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial

Clearmind Medicine (NASDAQ:CMND), a clinical-stage pharmaceutical company focused on developing novel psychedelic-derived therapies, announced today that its lead candidate, CMND-100, has successfully met the primary safety and tolerability endpoints in its Phase I/IIa clinical trial.

Read more: Clearmind Medicine hits primary safety endpoint in Phase I/IIa alcohol use disorder trial
Grafa

Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer

Genprex (NASDAQ:GNPX), a clinical-stage gene therapy company, announced today that its collaborators presented compelling preclinical data for its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Read more: Genprex preclinical data shows Reqorsa overcoming resistance in lung cancer

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift